Search

Pseudoephedrine

[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889.

Loperamide

Loperamide is an anti-diarrheal agent that is available as an over-the-counter product for treating diarrhea.[L42785] The drug was first synthesized in 1969 and used medically in 1976. … [A251610] It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss.

Sotatercept

Sotatercept is an activin signalling inhibitor. … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.

Capsaicin

Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements … The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Rurioctocog alfa pegol

Bleeding in joints is a common manifestation of hemophilia A, and bleeding episodes can be severe and life-threatening like intracranial hemorrhage. … Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous

Albutrepenonacog alfa

[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]

Cabazitaxel

[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A260621] As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death.

Lonoctocog alfa

Antihemophilic factor (recombinant), PEGylated

PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].

Moroctocog alfa

Other drug products with similar structure and function to Moroctocog alfa include [DB13192], which is purified Factor VIII from human pooled blood and contains both A- and B-subunits, and [DB11607], which … Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia